Several new antibacterial candidates shared the stage with promising agents that augment antimicrobial drugs, combination agents that work better than their separate components, and antifungal candidate agents-presented this year during the poster summary session "Early New Antimicrobial Agents," convened at the 2016 ASM Microbe Meeting, held in Boston, Mass., in June. In addition, participants learned briefly about a new imaging approach for following the course of infections and the drugs or drug candidates that are used and being developed, respectively, to treat them. Although these new antimicrobial agents appear potentially useful, none of them looks startling or could be called a breakthrough.
Among the most intriguing of these new antibacterial candidates is SPR741, which is described as a promising "potentiator" of antibacterial activity-notably broadening the specifıcity of other antibacterial agents with which it is combined, according to Troy Lister of IHMA in Schaumberg, Ill., and his collaborators at Spero Therapeutics in Cambridge, Mass. This candidate antimicrobial agent is a modifıed version of polymyxin, a broad-spectrum antibiotic that can be damaging to host kidneys. When reconfıgured "to eliminate nephrotoxicity," however, its antimicrobial activity is sharply reduced. Thus, to be effective, SPR741 needs to be combined with other antibacterial agents, including some that are best known for being active against grampositive pathogens. Among them, rifamycin seems to "work best" in combination with SPR741, he says. Another plus is that "we could not identify any toxicity" with this combination when tested on nonhuman primates, Lister adds. Whether that combination or others will prove active against pathogens that are resistant to polymyxin antibiotics is not yet known.
Another more conventional antibacterial candidate is Lascufloxacin-a "novel fluoroquinolone with remarkable pulmonary distribution," says Ryuta Kishi of Kyorin Pharmaceuticals in Tokyo, Japan. It has "potent activity" against many gram-positive bacterial pathogens
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Recent developments involving microbiology and related science policy matters as well as drug, vaccine, and diagnostic product approvals include:
• U.S. Food and Drug Administration (FDA) officials in June approved Xpert Carba-R Assay, an infection control aid that tests patient specimens to detect specific genetic markers associated with bacteria that are resistant to carbapenem antibiotics. and is also "active" against some gram negatives. In preclinical testing, it is active against methicillin-resistant Staphylococcus aureus and also macrolide-resistant pneumonia as well as against some anaerobes, he notes. When administered to "healthy human volunteers," the drug candidate is "remarkably distributed" throughout their lungs without "serious adverse effects." Tnp-2092, another antibacterial candidate, is dual-acting, targeting several pathogens that infect the gastrointestinal tract, including Helicobacter pylori and Clostridium diffıcile, according to Zhenkun Ma of Tennor Therapeutics in Shanghai, China, and his collaborators. The primary target of this molecule, which consists of a quinolone antibiotic that is linked to rifamycin, is DNA gyrase, while its secondary target is RNA polymerase, he says. WCK4873, or Nafıthromycin, is a novel lactone ketolide with a methylated side chain, according to Mahesh Patel of Wockhardt Research Center in Aurangabadad, India. This orally available drug is being developed for treating community-acquired cases of pneumonia, particularly among vulnerable elderly populations who are no longer so well protected by vaccination, he says. This agent "is good at penetrating the lung, better than telithromycin," and it yields "three logs" of killing when used against pneumonia in mice compared to telithromycin, which is bacteriostatic. The candidate ketolide, soon entering phase 2 clinical testing, appears to be safe for human use, he adds.
Meanwhile, WCK 5222 is a broadly active ␤-lactam antibiotic "enhancer," one in a series of such agents that can augment the activity of proven ␤-lactam antibiotics, including those to which bacterial pathogens are resistant because they produce ␤-lactamases, according to Patel of Wockhardt Research Center in India. When combined with such antibiotics, particularly cephalosporins, this particular enhancer provides "potent coverage" against a variety of multi-and extensively drug-resistant bacterial pathogens, including clinical isolates of Acinetobacter baumannii, Klebsiella, and Pseudomonas aeruginosa, he says. It is effective when used to treat lung and thigh infections of mice.
ETX2514 is another example of a ␤-lactamase inhibitor that can enhance the activity of ␤-lactam antibiotics, including against pathogens such as A. baumannii, according to Ruben Tommasi of Entasis Therapeutics in Waltham, Mass. This experimental agent has "excellent activity against A, C, and D" ␤-lactamase enzymes, he says. Based on preclinical testing, ETX2514 appears to work well when combined with sulbactam-itself a ␤-lactamase inhibitor-against A. baumannii, he notes. Thus, ETX2514 exhibits modest intrinsic antibacterial activity, which he says is "likely due" to its ability to inhibit penicillin-binding protein 2. More conventionally, this experimental agent is effective against P. aeruginosa when combined with imipenem.
Combining two antifungal agents may improve prospects for treating recalcitrant aspergillosis in patients, according to Vidmantis Petraitis of Weill Cornell Medical College in New York, N.Y., and his collaborators. They are testing the specifıc combination of Isavuconazole, an azole that interferes with fungal cell membrane development, and Micafungin, an echinocandin that blocks cell wall synthesis in Aspergillus fumigatus, a fungal pathogen that can be diffıcult to treat in humans, he says, "This combination leads to increased survival and decreased
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Dx-Recent Developments on the Diagnostic Front
Recent developments involving new means to detect microorganisms and to diagnose infectious diseases include:
• A rapid approach for testing blood for pathogens from patients suspected of being septic proves successful within one hour of sampling in 85% fumigatus among all groups of animals in all combination groups." Multispectral optoaccoustic tomography (MSOT) lies at the heart of a new approach for following pathogens when they infect animals as well as drugs used to treat those animals, according to Peter Panizzi of Auburn University in Auburn, Ala. MSOT, whose use he is helping to pioneer for analyzing infectious diseases, depends on infrared lasers to detect differentially dye-marked antimicrobial agents and pathogens, he says.
For example, a pathogen such as S. aureus can be marked with a bioluminescent dye, then injected into mice, and the course of that infection followed using this imaging technology. "You get a three-dimensional movable view of the animal, and see the infectious signal in different organs," Panizzi says. Similarly, drugs and drug candidates can be marked with different dyes to determine where they move throughout such animals and whether they are effective in reaching and then treating those pathogens. "We do not have a lot of conclusions, but to develop new drugs, we need to understand how a disease progresses," he says.
Jeffrey L. Fox is the Microbe Current Topics and Features Editor.
RESEARCH ADVANCES
Crystalized Proteins from Thermophile Reveal Transcription Insights Carol Potera
The recently determined three-dimensional (3D) structure of a bacterial class II transcription complex helps to reveal how it binds to specifıc DNA sequences, thus driving transcription of downstream genes. This X-ray-based structural analysis provides the fırst atomic structure for such an intact class II transcription activation complex, according to Richard About 30 years ago, Ebright began trying to crystallize the catabolite activator complex (CAP) from Escherichia coli-part of its transcription activation complex. Although that specifıc goal remains elusive, the Rutgers group used electron microscopy in 2009 to obtain a low-resolution structure of this class I transcription activation complex containing CAP from E. coli. However, unsuccessful efforts to crystallize those E. coli components frustrated their attempts to refıne those views.
A shift in strategy brought success. Thus, Ebright and his collaborators switched their attentions to comparable transcription components from Thermus thermophilus. This thermophile's TTHB099 activator protein (TAP), which is a homolog of CAP from E. coli, functions at higher temperatures than does CAP or other proteins from E. coli. 
